Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$85,520.00-0.35%ETH$2,697.04-0.63%GOLD$4,189.90+0.07%OIL$89.91+0.53%
Smart Investors Daily
SID Premium
CY

NASDAQ · CYCN

Cyclerion Therapeutics, Inc.

Healthcare · Biotechnology

$23.52

Up+$0.00 (+0.00%)

Updated Oct 7, 2026, 5:03 AM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
5.57M
P/E ratio
-2.45
Dividend yield
0.00%
52-week range
$1.03 – $36.33
Volume
62.49K
Avg. volume
695.98K

Price performance · CYCN

CYCN price history

1M range · 1 trading sessions · Daily adjusted prices

Prices through Sep 8, 2026

CYCN closed at $23.52 after 1 trading sessions, up 0.00% for the selected period.

No results

At least two price observations are needed to draw this chart.

Latest CYCN news

The latest Smart Investors Daily articles mentioning CYCN.

Stock researchCompany · Overview

CYCN research

Overview

Company profile and research snapshot.

Company profile

Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CYCN recent ratings
DateFirmRatingTarget
Oct 20, 2021Truist SecuritiesBuy—
Sep 24, 2021Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

Advancing lead program KRSA-028 toward the clinic, with Phase 1 healthy volunteer data expected mid-2027 and interim proof-of-concept data in Alzheimer’s patients anticipated by year-end 2027 or first quarter of 2028 Strong financial position with post-transaction cash and cash equivalents of approximately $475 million1 expected to fund operations into 2029 Shares to begin trading on Nasdaq under ticker symbol “KRSA” on September 9 WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Korsana Biosc

Yahoo · Feb 23, 2026

CYCN: Positive Feedback from FDA Sets Stage for Phase 2 Trial of CYC-126 in 2H26

By David Bautz, PhD NASDAQ:CYCN READ THE FULL CYCN RESEARCH REPORT Business Update Positive Regulatory Feedback Supports Phase 2 Trial Initiation in 2H26 On February 17, 2026, Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) announced that the U.S. Food and Drug Administration (FDA) provided positive written feedback to the company regarding the planned Phase 2 proof-of-concept clinical trial

Yahoo · Feb 17, 2026

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

–Received Positive Pre-Investigational New Drug (“IND”) Written Feedback from the U.S. Food and Drug Administration (“FDA”)– –Clinical Advisory Board (“CAB”) Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept (“POC”) Study in Treatment Resistant Depression (“TRD”) in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) (“Cyclerion

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By